JP2016538270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016538270A5 JP2016538270A5 JP2016526213A JP2016526213A JP2016538270A5 JP 2016538270 A5 JP2016538270 A5 JP 2016538270A5 JP 2016526213 A JP2016526213 A JP 2016526213A JP 2016526213 A JP2016526213 A JP 2016526213A JP 2016538270 A5 JP2016538270 A5 JP 2016538270A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cgvhd
- day
- administered
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 35
- 230000000153 supplemental effect Effects 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000003628 erosive effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895981P | 2013-10-25 | 2013-10-25 | |
| US61/895,981 | 2013-10-25 | ||
| US201361910945P | 2013-12-02 | 2013-12-02 | |
| US61/910,945 | 2013-12-02 | ||
| US201461973176P | 2014-03-31 | 2014-03-31 | |
| US201461973173P | 2014-03-31 | 2014-03-31 | |
| US61/973,173 | 2014-03-31 | ||
| US61/973,176 | 2014-03-31 | ||
| PCT/US2014/062277 WO2015061751A1 (en) | 2013-10-25 | 2014-10-24 | Methods of treating and preventing graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083275A Division JP6712427B2 (ja) | 2013-10-25 | 2019-04-24 | 移植片対宿主病を処置し予防する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016538270A JP2016538270A (ja) | 2016-12-08 |
| JP2016538270A5 true JP2016538270A5 (enExample) | 2017-11-30 |
Family
ID=52993667
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526213A Ceased JP2016538270A (ja) | 2013-10-25 | 2014-10-24 | 移植片対宿主病を処置し予防する方法 |
| JP2019083275A Active JP6712427B2 (ja) | 2013-10-25 | 2019-04-24 | 移植片対宿主病を処置し予防する方法 |
| JP2020091997A Active JP6869400B2 (ja) | 2013-10-25 | 2020-05-27 | 移植片対宿主病を処置し予防する方法 |
| JP2021067193A Active JP7090396B2 (ja) | 2013-10-25 | 2021-04-12 | 移植片対宿主病を処置し予防する方法 |
| JP2022095164A Active JP7465305B2 (ja) | 2013-10-25 | 2022-06-13 | 移植片対宿主病を処置し予防する方法 |
| JP2024054467A Pending JP2024099527A (ja) | 2013-10-25 | 2024-03-28 | 移植片対宿主病を処置し予防する方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019083275A Active JP6712427B2 (ja) | 2013-10-25 | 2019-04-24 | 移植片対宿主病を処置し予防する方法 |
| JP2020091997A Active JP6869400B2 (ja) | 2013-10-25 | 2020-05-27 | 移植片対宿主病を処置し予防する方法 |
| JP2021067193A Active JP7090396B2 (ja) | 2013-10-25 | 2021-04-12 | 移植片対宿主病を処置し予防する方法 |
| JP2022095164A Active JP7465305B2 (ja) | 2013-10-25 | 2022-06-13 | 移植片対宿主病を処置し予防する方法 |
| JP2024054467A Pending JP2024099527A (ja) | 2013-10-25 | 2024-03-28 | 移植片対宿主病を処置し予防する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (7) | US9795604B2 (enExample) |
| EP (2) | EP3060218A4 (enExample) |
| JP (6) | JP2016538270A (enExample) |
| KR (5) | KR20250162912A (enExample) |
| CN (2) | CN106102745B (enExample) |
| AU (5) | AU2014339815B2 (enExample) |
| CA (2) | CA3103411A1 (enExample) |
| EA (1) | EA201690745A1 (enExample) |
| IL (2) | IL245183B (enExample) |
| MX (2) | MX385122B (enExample) |
| PH (2) | PH12016500768B1 (enExample) |
| TW (1) | TWI620565B (enExample) |
| WO (1) | WO2015061751A1 (enExample) |
| ZA (1) | ZA202208792B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| KR20150032340A (ko) | 2012-07-24 | 2015-03-25 | 파마시클릭스, 인코포레이티드 | 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이 |
| US9795604B2 (en) * | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
| US20150157634A1 (en) * | 2013-12-02 | 2015-06-11 | Pharmacyclics, Inc. | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| US10793566B2 (en) | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| EA201891626A1 (ru) * | 2016-01-21 | 2019-04-30 | Зибо Биополар Чангшенг Фармасьютикал Ко. Лтд. | Ингибиторы тирозинкиназы брутона |
| CA3017567A1 (en) | 2016-03-11 | 2017-09-14 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating bruton's tyrosine kinase |
| US20180185421A1 (en) * | 2016-08-29 | 2018-07-05 | Tokyo Metropolitan Government | Composition comprising fecal microbiota |
| AU2018234827B2 (en) | 2017-03-15 | 2024-04-04 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| US20220354629A1 (en) * | 2018-01-09 | 2022-11-10 | E2Bio Life Sciences, Llc | Method and device for the enhancement of topical treatments for oral mucositis and other oral conditions |
| CN109481666B (zh) * | 2018-12-21 | 2020-11-03 | 江苏省中医院 | 一种人体血液肿瘤pdx模型的建立方法 |
| CN112439069A (zh) * | 2019-08-28 | 2021-03-05 | 江苏恒瑞医药股份有限公司 | 一种vegfr抑制剂在制备治疗移植物抗宿主病的药物中的用途 |
| US11433072B1 (en) | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
| WO2023014817A1 (en) | 2021-08-03 | 2023-02-09 | Syros Pharmaceuticals, Inc. | Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
| US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
| US6306897B1 (en) | 1999-03-19 | 2001-10-23 | Parker Hughes Institute | Calanolides for inhibiting BTK |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| PT1212327E (pt) | 1999-09-17 | 2004-01-30 | Abbott Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos |
| WO2001025238A2 (en) | 1999-10-06 | 2001-04-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| JP2003516351A (ja) | 1999-11-30 | 2003-05-13 | パーカー ヒューズ インスティテュート | コラーゲン誘導血小板凝集阻害剤 |
| EP1246829A1 (en) | 1999-12-17 | 2002-10-09 | Ariad Pharmaceuticals, Inc. | Novel heterocycles |
| GB0005345D0 (en) | 2000-03-06 | 2000-04-26 | Mathilda & Terence Kennedy Ins | Methods of treating sepsis septic shock and inflammation |
| WO2002038797A2 (en) | 2000-10-23 | 2002-05-16 | Bristol-Myers Squibb Company | Modulators of bruton's tyrosine kinase, their identification and use |
| CA2436570A1 (en) | 2000-12-06 | 2002-06-13 | Pharmacia Corporation | Rapidly dispersing pharmaceutical composition comprising effervescent agents |
| HUP0303538A2 (hu) | 2000-12-21 | 2005-02-28 | Bristol-Myers Squibb Co. | Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| AU2002315389A1 (en) | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
| US20030124028A1 (en) | 2001-08-10 | 2003-07-03 | Carlson Eric D. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| WO2003016338A1 (en) | 2001-08-15 | 2003-02-27 | Parker Hughes Institute | Crystal structure of the btk kinase domain |
| US20050084905A1 (en) | 2002-03-21 | 2005-04-21 | Prescott John C. | Identification of kinase inhibitors |
| SE0202461D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| US20050008640A1 (en) | 2003-04-23 | 2005-01-13 | Wendy Waegell | Method of treating transplant rejection |
| EP1473039A1 (en) | 2003-05-02 | 2004-11-03 | Centre National De La Recherche Scientifique (Cnrs) | Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| MY144339A (en) | 2003-09-08 | 2011-08-29 | Aventis Pharma Inc | Thienopyrazoles |
| US20050153990A1 (en) | 2003-12-22 | 2005-07-14 | Watkins William J. | Phosphonate substituted kinase inhibitors |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| CA2554551A1 (en) | 2004-01-26 | 2005-10-13 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US20050209284A1 (en) | 2004-02-12 | 2005-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tec kinase inhibitors |
| CA2581375A1 (en) | 2004-09-27 | 2006-04-06 | Kosan Biosciences Incorporated | Specific kinase inhibitors |
| US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| US20060182723A1 (en) * | 2005-01-25 | 2006-08-17 | Spellberg Brad J | Methods for treating refractory infections in neutropenic individuals |
| WO2007016977A1 (de) | 2005-08-05 | 2007-02-15 | Delica Ag | Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel |
| WO2007027594A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| EP1957491A2 (en) | 2005-11-12 | 2008-08-20 | Boehringer Ingelheim International GmbH | Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors |
| WO2007076228A2 (en) | 2005-12-20 | 2007-07-05 | Boehringer Ingelheim International Gmbh | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| AU2006336506B2 (en) * | 2006-01-13 | 2012-06-28 | Pharmacyclics Llc | Inhibitors of tyrosine kinases and uses thereof |
| CA2662074A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| EP2526934B1 (en) * | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP2089391B1 (en) | 2006-11-03 | 2013-01-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| US8809273B2 (en) | 2007-03-28 | 2014-08-19 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
| SG10202107066WA (en) * | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| JP5600063B2 (ja) | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| WO2010068806A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
| WO2011017219A1 (en) | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Imidazoquinoxalinones and anti-tumor treatment |
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
| EP2717887B1 (en) * | 2011-06-09 | 2017-12-27 | University of Florida Research Foundation, Inc. | Methods for treating or preventing graft versus host disease |
| US20130178483A1 (en) * | 2011-06-28 | 2013-07-11 | Pharmacyclics, Inc. | Methods and Compositions for Inhibition of Bone Resorption |
| EP2771010A4 (en) * | 2011-10-19 | 2015-04-01 | Pharmacyclics Inc | USE OF BRUTON TYROSINE KINASE (BTK) INHIBITORS |
| EP2788020A4 (en) | 2011-12-05 | 2015-04-29 | Immunomedics Inc | THERAPEUTIC USE OF ANTI-CD22 ANTIBODIES FOR THE INDUCTION OF TROGO CYTOSIS |
| HK1206624A1 (en) * | 2012-04-11 | 2016-01-15 | Acerta Pharma B.V. | Bruton's tyrosine kinase inhibitors for hematopoietic mobilization |
| AU2013266069B2 (en) | 2012-05-25 | 2018-03-15 | Sloan Kettering Institute For Cancer Research | Methods for treating GI syndrome and graft versus host disease |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| WO2014004707A1 (en) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| US9658228B2 (en) * | 2013-01-30 | 2017-05-23 | The Board of Trustees of the Leland University Junior University | Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients |
| WO2014127200A1 (en) * | 2013-02-15 | 2014-08-21 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| JP2016512549A (ja) * | 2013-03-14 | 2016-04-28 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ |
| AU2014251028A1 (en) * | 2013-04-08 | 2015-11-05 | Janssen Pharmaceutica Nv | Ibrutinib combination therapy |
| US9795604B2 (en) | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
| US20150157634A1 (en) * | 2013-12-02 | 2015-06-11 | Pharmacyclics, Inc. | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
-
2014
- 2014-10-24 US US14/523,650 patent/US9795604B2/en active Active
- 2014-10-24 AU AU2014339815A patent/AU2014339815B2/en active Active
- 2014-10-24 EP EP14856623.5A patent/EP3060218A4/en not_active Withdrawn
- 2014-10-24 KR KR1020257036179A patent/KR20250162912A/ko active Pending
- 2014-10-24 MX MX2016005294A patent/MX385122B/es unknown
- 2014-10-24 JP JP2016526213A patent/JP2016538270A/ja not_active Ceased
- 2014-10-24 KR KR1020237041412A patent/KR20230170797A/ko active Pending
- 2014-10-24 CA CA3103411A patent/CA3103411A1/en active Pending
- 2014-10-24 MX MX2021009400A patent/MX392373B/es unknown
- 2014-10-24 WO PCT/US2014/062277 patent/WO2015061751A1/en not_active Ceased
- 2014-10-24 KR KR1020167013594A patent/KR102357526B1/ko active Active
- 2014-10-24 EP EP22179611.3A patent/EP4115886A1/en active Pending
- 2014-10-24 KR KR1020227002810A patent/KR102452866B1/ko active Active
- 2014-10-24 CA CA2928721A patent/CA2928721C/en active Active
- 2014-10-24 KR KR1020227034478A patent/KR102671643B1/ko active Active
- 2014-10-24 CN CN201480068676.2A patent/CN106102745B/zh active Active
- 2014-10-24 EA EA201690745A patent/EA201690745A1/ru unknown
- 2014-10-24 CN CN202010072071.8A patent/CN111265531B/zh active Active
- 2014-10-24 TW TW103136912A patent/TWI620565B/zh active
-
2016
- 2016-04-18 IL IL245183A patent/IL245183B/en unknown
- 2016-04-25 PH PH12016500768A patent/PH12016500768B1/en unknown
-
2017
- 2017-05-03 US US15/586,058 patent/US10463668B2/en active Active
-
2019
- 2019-04-24 JP JP2019083275A patent/JP6712427B2/ja active Active
- 2019-09-25 US US16/582,945 patent/US10695350B2/en active Active
-
2020
- 2020-05-27 JP JP2020091997A patent/JP6869400B2/ja active Active
- 2020-06-12 US US16/900,624 patent/US20210121463A1/en not_active Abandoned
- 2020-06-26 AU AU2020204270A patent/AU2020204270A1/en not_active Abandoned
-
2021
- 2021-01-08 PH PH12021550052A patent/PH12021550052A1/en unknown
- 2021-04-12 JP JP2021067193A patent/JP7090396B2/ja active Active
- 2021-08-24 IL IL285843A patent/IL285843A/en unknown
-
2022
- 2022-04-22 AU AU2022202686A patent/AU2022202686B2/en active Active
- 2022-04-27 US US17/730,764 patent/US20230097340A1/en not_active Abandoned
- 2022-06-13 JP JP2022095164A patent/JP7465305B2/ja active Active
- 2022-08-05 ZA ZA2022/08792A patent/ZA202208792B/en unknown
-
2023
- 2023-09-25 US US18/372,398 patent/US20240293408A1/en not_active Abandoned
- 2023-11-30 AU AU2023274176A patent/AU2023274176B2/en active Active
-
2024
- 2024-03-28 JP JP2024054467A patent/JP2024099527A/ja active Pending
- 2024-12-19 US US18/987,370 patent/US20250345335A1/en active Pending
-
2025
- 2025-11-10 AU AU2025263907A patent/AU2025263907A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016538270A5 (enExample) | ||
| JP2017501848A5 (enExample) | ||
| JP2014506321A5 (enExample) | ||
| JP2016518337A5 (enExample) | ||
| JP2015157821A5 (enExample) | ||
| JP2017075173A5 (enExample) | ||
| JP2013147511A5 (enExample) | ||
| JP2015516456A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2019530713A5 (enExample) | ||
| JP2016512817A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2019531293A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| JP2016537338A5 (enExample) | ||
| JP2014210824A5 (enExample) | ||
| JP2015522603A5 (enExample) | ||
| JP2017529355A5 (enExample) | ||
| JP2016531853A5 (enExample) | ||
| JP2019528290A5 (enExample) | ||
| Zhang et al. | Fecal Microbiota Transplantation Modulates Th17/Treg Balance via JAK/STAT Pathway in ARDS Rats | |
| JP2017511372A5 (enExample) | ||
| JP2016514142A5 (enExample) | ||
| JP2018531967A5 (enExample) | ||
| Khalid | Serositis, pleural effusion and severe pulmonary arterial hypertension: case report |